Gallbladder Carcinoma
Conditions
Brief summary
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Detailed description
Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study. These information will be used to recommend target therapy which may be more likely to result in a beneficial response. Patients will receive target antitumor agents according to the result of genomic and proteomic profiling and be monitored by circulating tumor DNA(ctDNA).
Interventions
DRUGgemcitabine and oxaliplatin.
GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
DRUGAfatinib
Target therapy Drug: afatinib
Sponsors
Shanghai Zhongshan Hospital
Ruijin Hospital
RenJi Hospital
Qilu Hospital of Shandong University
The First Affiliated Hospital of Anhui Medical University
Shanghai East Hospital of Tongji University
Changshu Affiliated Hospital of Soochow University
Qinghai People's Hospital
The Second People's Hospital of Baoshan, Yunnan Province
Lanzhou University Second Hospital
The Affiliated Hospital of Inner Mongolia Medical University
The First People's Hospital of Nantong
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Chinese# * Stable vital signs, ECOG:0-1; * Patients have a diagnosis of resectable gallbladder carcinoma by histopathology or cytopathology after radical surgery. * Adequate fresh tumor tissue for genome sequencing and immunohistochemistry test; harboring mutations or abnormal activation of erb-b2 receptor tyrosine kinase signal pathway components * Life expectancy of more than 18 weeks; * T stage≥ T2 or histopathological lymph node positive according to AJCC (8th edition) staging. * Adequate hepatic, hematologic and renal functions(ALT≤5×upper limit of normal (ULN), AST≤5×ULN, the Child-Pugh classification for class A or B, white blood cells≥3×10\^9/L, neutrophils≥1.5×10\^9/L, platelets≥75×10\^9/L , hemoglobin ≥ 90g/L, creatinine clearance rate≥60ml/min; * Volunteer for this study, have written informed consent and have good Patient compliance; * Female patients of childbearing potential and their mates agree to avoid pregnancy.
Exclusion criteria
* Have received following treatment before this study: a. Anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; b. lesions have been treated by irradiation; c. participate in other therapeutic or interventional clinical trials. * History of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years; * Have serious concurrent illness including, but not limited to uncontrolled congestive heart failure(NYHA classification grade III or IV), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure \>21.3 Kpa or diastolic blood pressure \>13.3 Kpa); * Have ongoing or active serious infection; * Have uncontrolled diabetes mellitus; * Psychiatric illness which potentially hamper the ability to willingly give written informed consent and compliance with the study protocol; * Active autoimmune diseases require long-term use of steroids or received allotransplantation * Other serious illness considered not suitable for this study by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year DFS | up to 3 years | 3-year disease free survival rates:The progression is defined consistent with contrast enhanced MRI/CT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 3-year OS | up to 3 years | 3-year Overall survival rates |
Other
| Measure | Time frame | Description |
|---|---|---|
| sensitivity and specificity of ctDNA | up to 2 years | sensitivity and specificity of ctDNA compared to clinical index（CA199，CEA）for monitoring tumour progression |
Countries
China
Contacts
Primary ContactYingbin Liu, PHD
Outcome results
None listed